SLN

Silence Therapeutics is a pre-commercial siRNA biotech whose value lives entirely in its pipeline, not its P&L — the P/S of 2633x is a meaningless artifact of collapsed collaboration revenue ($43.3M in FY2024 down to $559K in FY2025, -98.7%). Judged as a business, this is a cash-burning research shop: FY2025 net loss of -$88.6M (nearly double FY2024's -$45.3M), operating cash flow of -$62.3M, R&D holding at $67.8M, and a retained-earnings deficit of -$563M. Return on equity is -142% and equity has been halved (-53.5%) in a single year. None of the three lenses — fundamentals, valuation, price action — can be assessed conventionally; this is a probability-weighted pipeline bet.

The balance sheet is the crux and it is precarious. Cash & equivalents fell 90.7% to just $11.3M against a $62.3M annual burn. Current assets of $119M (vs. $13.6M current liabilities) imply roughly $108M sits in near-cash marketable securities, which stretches runway to perhaps ~1.5–2 years — but the 90.7% cash draw-down and the halving of equity signal a company that must raise capital, almost certainly through dilution, likely around the very catalyst investors are waiting for. That financing overhang caps upside even in a good scenario.